- Home
- CTMX vs MYGN Comparison
CTMX vs MYGN Comparison
Compare CTMX & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- MYGN
- Stock Information
- Founded
- CTMX 2008
- MYGN 1991
- Country
- CTMX United States
- MYGN United States
- Employees
- CTMX N/A
- MYGN N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CTMX Health Care
- MYGN Health Care
- Exchange
- CTMX Nasdaq
- MYGN Nasdaq
- Market Cap
- CTMX 596.2M
- MYGN 625.5M
- IPO Year
- CTMX 2015
- MYGN 1995
- Fundamental
- Price
- CTMX $3.64
- MYGN $6.65
- Analyst Decision
- CTMX Strong Buy
- MYGN Hold
- Analyst Count
- CTMX 6
- MYGN 14
- Target Price
- CTMX $6.50
- MYGN $13.23
- AVG Volume (30 Days)
- CTMX 3.9M
- MYGN 1.1M
- Earning Date
- CTMX 11-06-2025
- MYGN 11-03-2025
- Dividend Yield
- CTMX N/A
- MYGN N/A
- EPS Growth
- CTMX 50.22
- MYGN N/A
- EPS
- CTMX 0.24
- MYGN N/A
- Revenue
- CTMX $113,631,000.00
- MYGN $825,300,000.00
- Revenue This Year
- CTMX N/A
- MYGN $0.06
- Revenue Next Year
- CTMX N/A
- MYGN $5.68
- P/E Ratio
- CTMX $15.28
- MYGN N/A
- Revenue Growth
- CTMX N/A
- MYGN 0.21
- 52 Week Low
- CTMX $0.40
- MYGN $3.76
- 52 Week High
- CTMX $4.62
- MYGN $16.83
- Technical
- Relative Strength Index (RSI)
- CTMX 50.34
- MYGN 42.28
- Support Level
- CTMX $3.35
- MYGN $6.25
- Resistance Level
- CTMX $4.45
- MYGN $6.89
- Average True Range (ATR)
- CTMX 0.37
- MYGN 0.44
- MACD
- CTMX -0.06
- MYGN -0.06
- Stochastic Oscillator
- CTMX 30.00
- MYGN 26.27
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.